scholarly journals The role of interleukins 17, 23 and antibodies to the thyroid-stimulating hormone receptor in the pathogenesis of endocrine ophthalmopathy

2018 ◽  
Vol 14 (2) ◽  
pp. 72-80
Author(s):  
Svetlana V. Charinzeva ◽  
Elizaveta S. Taskina
Keyword(s):  
Hormone Receptor ◽  
Comparison Group ◽  
Study Groups ◽  
Thyroid Stimulating Hormone ◽  
Control Group ◽  
Clinical Activity ◽  
Clinical Group ◽  
Endocrine Ophthalmopathy ◽  
Stimulating Hormone

Background. Endocrine ophthalmopathy (EOP) is an autoimmune orbit disease characterized by soft retrobulbar tissues damage. The level of antibodies to the thyroid-stimulating hormone receptor (TSHRAbs) is considered as a laboratory marker of EOP activity. Interleukins 17 (IL-17) and 23 (IL-23) play an important role in the pathogenesis of some autoimmune diseases and directly correlate with clinical activity. At present, there is an open question about the role of these cytokines in EOP and their relationship with TSHRAbs. Aims. To assess pathogenetic role of IL-17, IL-23 and TSHRAbs in patients with EOP. Materials and methods. The study included 50 people (100 eyes) at the age of 43 [35; 50] years. Three study groups were formed: 32 patients with moderate severity of EOP (clinical group), 18 patients with thyroid pathology without EOP (comparison group) and 15 healthy subjects (control group). All groups were comparable in age and sex. The diagnosis was verified clinically, laboratory and instrumentally. A comprehensive ophthalmologic examination and blood sampling were performed to determine the concentrations of IL-17, IL-23 and TSHRAbs. Statistical processing of the data was carried out in the program “Statistica 10.0”, StatSoft, Inc. Results. An increase in the level of TSHRAbs was observed in all phases of EOP activity in comparison with both comparison group and control (p < 0.05). But in the active phase TSHRAbs level reached the maximum values in 100% of patients. An increase in the IL-17 concentration in 5,3 times was found in the active EOP in comparison with the control group (p < 0.05). Concentration of TSHRAbs and IL-17 in blood serum directly correlates with EOP activity (p < 0.001). After carrying out pulse therapy with glucocorticosteroids, the consentration of IL-17 decreased almost to zero. There were no significant differences in the level of IL-23 in the groups (p = 0.56). Conclusions. Determination of TSHRAbs and IL-17 levels in serum can be used as a laboratory diagnostic marker of EOP activity.  

Role of micronutrient deficiency in development of heart disease in Graves’ disease

2020 ◽  
Vol 1 (19) ◽  
pp. 70-76
Author(s):  
L. V. Kvitkova ◽  
D. S. Vinichenko ◽  
S. A. Smakotina
Keyword(s):  
Ultrasound Examination ◽  
Selenium Deficiency ◽  
Cardiovascular Complications ◽  
Thyroid Stimulating Hormone ◽  
The Body ◽  
Control Group ◽  
Diagnostic Model ◽  
Graves Disease ◽  
Stimulating Hormone

Purpose. To assess the contribution of impaired supply of the body with zinc, selenium and copper to the development of cardiovascular complications in patients with Graves’ disease (HD). Methods. The study included 113 women aged 25–60 years with a diagnosis of HD: 54.0 % (n = 61) with moderate thyrotoxicosis, 46.0 % (n = 52) with severe. The duration of the disease is 1–5 years. The control group consisted of 37 women 25–60 years old without thyroid pathology and cardiovascular complications (CVC). All patients were assessed: in the blood – the level of thyroid-stimulating hormone, free thyroxine, the concentration of antibodies to the thyroid-stimulating hormone receptor; in the hair – the concentration of zinc, selenium, copper; results of ultrasound examination of the thyroid gland, echocardiography, 24-hour monitoring of electrocardiography. Results. Selenium deficiency was found in AF in 70.9% of cases (n = 22), zinc in 77.4 % (n = 24), copper in 67.7 % (n = 21) of cases, in CHF, selenium deficiency in 76.9% (n = 40), zinc – 82.7 % (n = 43), copper – 76.9 % (n = 40). In the control group, selenium deficiency was detected in 15.5% (n = 6) (p = 0.01), zinc deficiency – in 27.0% (n = 10) (p = .01), copper deficiency – in 10.8 % (n = 4) (p = 0.01) cases. Using logistic regression, a diagnostic model and a table of CHF risk factors in points were compiled, taking into account the levels of selenium, zinc, copper in the hair. It is advisable to use the table in all patients with HD to determine the degree of risk of CHF; with an average and high risk of developing CHF, it is recommended to include preparations of selenium, zinc, copper in the treatment regimen for HD. Conclusion. The results obtained show that the deficiency of these microelements increases the likelihood of a severe course of HD, the development of CVO, and requires diagnosis and correction.

scholarly journals Significance of hyperprolactinemia for cytomorphologic features of breast secretions

2010 ◽  
Vol 67 (1) ◽  
pp. 42-47
Author(s):  
Danijela Radojkovic ◽  
Slobodan Antic ◽  
Milica Pesic ◽  
Milan Radojkovic ◽  
Dijana Basic ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Nipple Discharge ◽  
Thyroid Stimulating Hormone ◽  
Serum Prolactin ◽  
Control Group ◽  
Clinical Group ◽  
Group I ◽  
Stimulating Hormone

Background/Aim. Nipple discharge syndrome is a clinical entity capable of presenting various disorders such is mammary infection (nonpuerperal and puerperal mastitis), intraductal papillomas, fibrodenoma, breast cancer and hyperprolactinemia syndrome. The aim of the study was to determine differencies in cytological features of mammary secretion in patients with hyperprolactinemia and those with normal serum prolactin levels and to define the role of growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone in creating cellular profile of breast secretion. Methods. The study included 50 patients with nipple discharge syndrome. The patients were devided into the clinical group (27 patients with hyperprolactinemia and nipple discharge) and the control group I (23 patients with normal serum prolactin and nipple discharge). The control group II included the patients of the clinical group achiving normalised serum prolactin levels after the treatment of hyperprolactinemia. Serum prolactin, follicle-stimulating hormone and luteinizing hormone levels were assessed by RIA using commercial kits IRMA hPRL, hLH and hFSH, (INEP, Zemun, Serbia) while serum growth hormone and thyroid-stimulating hormone levels were assessed by RIA using commercial kits LKB-wallac. Cytologic evaluation of samples, taken from all the patients with mammary secretion, was done using standard techniques of staining Haemathoxilin-eozine and May- Gr?nwald/Giemsa. Results. Our results showed a significantly higher presence of lipid and protein material in clinical group, in comparison with the control group I (p < 0.01). Also, our data demonstrated significantly higher number of ductal epithelial cells (p < 0.05) and ductal histiocities (p < 0.001) in the clinical group, compared with the control group I. Macrophagies frequency was proportionally higher in clinical group (44.44%) compared the control group I (17.39%). Erythrocites were significantly lower in the clinical group (p < 0.001) than in the control group I. Significantly decreased mammary secretion (p < 0.01), lower lipid (p < 0.01) and protein synthesis (p < 0.01), and less presence of all cellular categories (p < 0.01) were obtained after normalization of serum prolactin levels. Conclusion. Growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone did not show significant influence on creating cytological features of mammary secretion. The most expressive role, hyperprolactinemia demonstrated in the domain of mammary ductal secretory activity, making mammary secretion reach in lipid and protein material and simultaneously increasing number of ductal epithelial cells, ductal histiocytes and 'foam cells'- macrophages. These cytological findings indicate that hyperprolactinemia promote periductal and intraductal steril inflammation which withdraws after serum prolactin normalization.

Differential Transcriptional and Protein Expression of Thyroid-Stimulating Hormone Receptor in Ovarian Carcinomas

2014 ◽  
Vol 24 (5) ◽  
pp. 851-856 ◽  
Author(s):  
Gyftaki Revekka ◽  
Liacos Christina ◽  
Politi Ekaterini ◽  
Liontos Michalis ◽  
Saltiki Katerina ◽  
...  
Keyword(s):  
Protein Expression ◽  
Hormone Receptor ◽  
Thyroid Stimulating Hormone ◽  
Surface Epithelium ◽  
Ovarian Carcinomas ◽  
Thyroid Cells ◽  
Protein Levels ◽  
Ovarian Carcinogenesis ◽  
Stimulating Hormone

ObjectiveThyroid-stimulating hormone (TSH) regulates normal thyroid function by binding to its receptor (thyroid-stimulating hormone receptor -TSHR) that is expressed at the surface of thyroid cells. Recently, it has been demonstrated that TSHR is abundantly expressed in several tissues apart from the thyroid, among them the normal ovarian surface epithelium. The role of TSHR expression outside the thyroid is not completely understood. The current study examines possible alterations of TSHR expression in ovarian carcinomas and its implication in ovarian carcinogenesis.Materials and MethodsQuantitative real-time polymerase chain reaction and immunohistochemistry analysis of TSHR expression were performed in 34 ovarian carcinoma specimens and 10 normal ovarian tissues (controls).ResultsSignificant reduction in TSHR messenger RNA (mRNA) expression was detected in ovarian carcinomas (mean [SD]: 0.518 [0.0934] vs normal, 49.4985 [89.1626];P< 0.001, Mann-WhitneyUtest), whereas TSHR protein levels were significantly increased (percentage of positive cells: cancer, 73.55% [20.09%], vs normal, 54.54% [21.14%]; intensity: cancer, 2.52 [0.508], vs normal 1 [0];P= 0.012, Mann-WhitneyUtest). No significant differences in TSHR mRNA were found according to history of thyroid disease.ConclusionsOur study describes for the first time alterations in TSHR expression both at mRNA and protein levels in ovarian carcinomas. The discrepancy between the decreased levels of the TSHR mRNA and the increased protein expression has already been described in thyroid carcinomas and might be due to alterations in its degradation by the ubiquitin system or other unknown mechanisms. Further analysis could elucidate the role of these findings in ovarian carcinogenesis.

scholarly journals Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Nan Yu ◽  
Yadi Zhang ◽  
Lei Kang ◽  
Ying Gao ◽  
Junqing Zhang ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Choroidal Thickness ◽  
Thyroid Stimulating Hormone ◽  
Spectral Domain ◽  
Control Group ◽  
Clinical Activity ◽  
Thyroid Function Tests ◽  
Optical Coherence ◽  
Graves Ophthalmopathy ◽  
Stimulating Hormone

Objectives. The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves’ ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT). Methods. The right eyes of 36 patients (27 females and 9 males) with Graves’ ophthalmopathy (GO) and those of 36 age-, gender-, and diopter-level-matched healthy participants were evaluated. The patients’ data were obtained within 3 months after the onset of Graves’ disease (GD). Thyroid hormone levels and thyroid-stimulating hormone receptor antibody (TRAb) levels were measured, and the degree of exophthalmos was measured in all patients. Activity is measured by the clinical activity score (CAS). A horizontal scan centered on the fovea was performed in all participants. Five points of choroidal thickness were measured at the fovea (SFCT) and at 1500 μm nasal (N1500), 3000 μm nasal (N3000), 1500 μm temporal (T1500), and 3000 μm temporal (T3000) to the fovea. Results. The CT measurements obtained were (mean ± SD) 313.47 ± 100.32 μm, 279.22 ± 85.80 μm, 214.64 ± 75.52 μm, 313.19 ± 80.36 μm, and 298.14 ± 82.75 μm in patients with GO and were 256.33 ± 50.18 μm, 223.14 ± 59.61 μm, 176.69 ± 60.66 μm, 250.92 ± 52.184 μm, and 239.47 ± 60.35 μm in the control group at the foveal, N1500, N3000, T1500, and T3000 measurement points, respectively. The CT in GO patients was significantly increased at all the points compared with the control group (P<0.05). There was no relationship between the CT and CAS, the degree of exophthalmos, triiodothyronine (T3), tetraiodothyronine (T4), thyroid-stimulating hormone (TSH), or TRAb levels in GO. Conclusions. CT was found to be increased in GO patients and had poor relationship with CAS, exophthalmos, and thyroid function tests.

scholarly journals The role of quantitative deep capillary plexus in the pathogenesis of type 3 macular neovascularization: an optical coherence tomography angiography study

2021 ◽  
Author(s):  
Marina Concilio ◽  
Federica Fossataro ◽  
Daniela Montorio ◽  
Mariapaola Giordano ◽  
Gilda Cennamo
Keyword(s):  
Optical Coherence Tomography ◽  
Optical Coherence Tomography Angiography ◽  
Early Stage ◽  
Study Groups ◽  
Control Group ◽  
Main Role ◽  
Optical Coherence ◽  
Capillary Plexus ◽  
Type 3

Abstract Purpose To quantitatively investigate the role of deep capillary plexus (DCP) in patients affected by type 3 macular neovascularization (MNV), compared to patients with reticular pseudodrusen (RPD) eyes and healthy controls, using optical coherence tomography angiography (OCTA). Methods In this prospective observational study, a total of seventy-eight eyes of 78 patients were included. Group 1 consisted of 40 eyes of 40 patients with stage 1 of type 3 MNV (22 males, 18 females, mean age 73.7, SD ± 6.60) and group 2 included 38 eyes of 38 patients with RPD (17 males, 21 females, mean age 73.2, SD ± 4.55). The control group included 40 eyes of 40 healthy subjects (20 males, 20 females, mean age 71.4, SD ± 6.36 years). We evaluated the retinal vessel density (VD) of superficial capillary plexus (SCP) and deep capillary plexus (DCP) using OCTA. Results Patients with diagnosis of type 3 MNV showed statistically lower values of VD in DCP with respect to controls and to RPD group (p < 0.001), while there were no statistical differences between RPD and control group in macular region. No significant differences in VD of SCP were detected among the three study groups. Conclusion OCTA provides a reproducible, non-invasive detailed quantitative analysis of retinal vascular features and changing in early-stage type 3 MNV patients, which allowed to shed the light on the main role of DCP ischemia in the development of type 3 MNV.

Sign in / Sign up

Export Citation Format

Share Document